论文部分内容阅读
目的探讨孟鲁司特钠辅助治疗支气管哮喘的疗效和安全性分析。方法选取本院从2013年2~12月收治的88例支气管哮喘患者,随机分为两组:对照组44例,给予舒利迭吸入治疗;治疗组44例,给予孟鲁司特钠联合舒利迭治疗。治疗12周之后,观察两组患者肺功能变化及疗效。结果治疗前后,治疗组和对照组组内比较,FEV1、FVC、PEF差异具有统计学意义(P<0.05);组间比较,差异无统计学意义(P>0.05);两组总有效人为43例和38例,总有效率分别为97.7%和86.4%,差异具有统计学意义(P<0.05)。结论孟鲁司特钠能够有效的改善支气管哮喘患者肺功能、提高临床疗效,且安全性较好。
Objective To investigate the efficacy and safety of Montelukast adjuvant therapy for bronchial asthma. Methods A total of 88 patients with bronchial asthma who were treated in our hospital from February to December 2013 were randomly divided into two groups: control group (44 cases), treatment with sullytrae inhalation (44 cases), montelukast Diego treatment. After 12 weeks of treatment, pulmonary function changes and therapeutic effects were observed in both groups. Results Before and after treatment, there were significant differences in FEV1, FVC and PEF between the treatment group and the control group (P <0.05); there was no significant difference between the two groups (P> 0.05) Cases and 38 cases, the total effective rate was 97.7% and 86.4%, the difference was statistically significant (P <0.05). Conclusion Montelukast sodium can effectively improve pulmonary function in patients with bronchial asthma, improve clinical efficacy and safety.